ARS Pharmaceuticals (SPRY) Capital Expenditures Growth (5y) (2025)

ARS Pharmaceuticals (SPRY) Capital Expenditures Growth (5y) (2025) Analysis & Trends

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Oculis Holding AG	68,184.45 Bn	68,184.17 Bn	-
2	Nanobiotix	1,953.19 Bn	1,953.13 Bn	-
3	Akari Therapeutics	1,132.35 Bn	1,132.35 Bn	-
4	BeOne Medicines	474.39 Bn	469.59 Bn	1.35 Bn
5	Vertex Pharmaceuticals	123.45 Bn	116.21 Bn	2.59 Bn
6	Regeneron Pharmaceuticals	69.92 Bn	61.16 Bn	3.31 Bn
7	Belite Bio	63.43 Bn	63.43 Bn	-
8	Argenx Se	56.67 Bn	51.49 Bn	1.41 Bn
9	Revolution Medicines	38.08 Bn	38.08 Bn	-
10	ARS Pharmaceuticals	585.25 Mn	384.28 Mn	-

Download Data